Whalesbook
Amey Chalke, Pharma Research Analyst at JM Financial Institutional Securities, shared his investment preferences for the Indian pharma sector. He favors hospitals due to structural tailwinds and formalization, expecting 15-20% growth. Contract Development and Manufacturing Organizations (CDMOs) are his second choice, with larger players being safer bets. He ranks generics last due to upcoming competitive pressures, including patent expiries, projecting muted earnings for large companies. Chalke also sees a ₹15,000 crore opportunity in India's semaglutide market.